Cellectis Beheer

Beheer criteriumcontroles 3/4

De CEO Cellectis is Andre Choulika, benoemd in Jan1999, heeft een ambtstermijn van 25.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 876.60K, bestaande uit 99.8% salaris en 0.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.02% van de aandelen van het bedrijf, ter waarde $ 2.01M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.3 jaar en 7.7 jaar.

Belangrijke informatie

Andre Choulika

Algemeen directeur

US$876.6k

Totale compensatie

Percentage CEO-salaris	99.8%
Dienstverband CEO	25.8yrs
Eigendom CEO	1.0%
Management gemiddelde ambtstermijn	4.3yrs
Gemiddelde ambtstermijn bestuur	7.7yrs

Recente managementupdates

Recent updates

Cellectis: Cheap With Promising But Speculative Cancer Therapies

Aug 30

Cellectis: 2 Data Readouts Of Blood Cancer Studies By End Of 2024

May 30

FDA clears Cellectis' investigational new drug application for lymphoma treatment

Aug 01

Cellectis Offers An Idiosyncratic Risk Profile With Remarkable Upside Potential

Jul 13

Cellectis: FYE 2021 TALEN CAR-T Data Announcement Should Catalyse Strong Upside

Jun 22

Cellectis outlines four new UCART preclinical programs; reveals .HEAL, a genome surgery platform

Jun 15

Cellectis withdraws follow-on offering

Dec 16

Cellectis initiates equity raise of $100M

Dec 14

FDA lifts clinical hold on Cellectis' early-stage UCARTCS1 study in multiple myeloma

Nov 18

Cellectis EPS misses by $0.10, misses on revenue

Nov 05

Analyse CEO-vergoeding

Hoe is Andre Choulika's beloning veranderd ten opzichte van Cellectis's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$84m
Jun 30 2024	n/a	n/a	-US$79m
Mar 31 2024	n/a	n/a	-US$78m
Dec 31 2023	US$877k	US$875k	-US$109m
Sep 30 2023	n/a	n/a	-US$92m
Jun 30 2023	n/a	n/a	-US$97m
Mar 31 2023	n/a	n/a	-US$91m
Dec 31 2022	US$744k	US$744k	-US$91m
Sep 30 2022	n/a	n/a	-US$63m
Jun 30 2022	n/a	n/a	-US$78m
Mar 31 2022	n/a	n/a	-US$99m
Dec 31 2021	US$879k	US$879k	-US$86m
Sep 30 2021	n/a	n/a	-US$129m
Jun 30 2021	n/a	n/a	-US$121m
Mar 31 2021	n/a	n/a	-US$113m
Dec 31 2020	US$1m	US$1m	-US$37m
Sep 30 2020	n/a	n/a	-US$79m
Jun 30 2020	n/a	n/a	-US$66m
Mar 31 2020	n/a	n/a	-US$67m
Dec 31 2019	US$1m	US$1m	-US$102m

Compensatie versus markt: De totale vergoeding ($USD 876.60K ) Andre } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.45M ).

Compensatie versus inkomsten: De vergoeding van Andre is gestegen terwijl het bedrijf verliesgevend is.

CEO

Andre Choulika (59 yo)

25.8yrs

Tenure

US$876,597

Compensatie

Dr. Andre Choulika, Ph.D. is the Founder of Cellectis S.A. and has been its Chief Executive Officer since 1999 and served as its Chairman since 2011 until November 5, 2020. He is the Director of Cellectis...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Andre Choulika	Co-Founder	25.8yrs	US$876.60k	1.02% $ 2.0m
David j. Sourdive	Deputy CEO	no data	US$557.84k	0.31% $ 606.4k
Arthur Stril	Interim Chief Financial Officer	less than a year	geen gegevens	0.0086% $ 17.0k
Valerie Cros	Principal Financial Officer & Principal Accounting Officer	2.9yrs	geen gegevens	geen gegevens
Jean Epinat	Chief Technological Officer	no data	geen gegevens	geen gegevens
Philippe Duchateau	Chief Scientific Officer	12.8yrs	geen gegevens	0.043% $ 85.5k
Marie-Bleuenn Terrier	General Counsel & Secretary of the Board of Directors	11.8yrs	geen gegevens	0.031% $ 60.5k
Pascalyne Wilson	Director of Communications	no data	geen gegevens	geen gegevens
Kyung Nam-Wortman	Executive VP & Chief Human Resources Officer	4yrs	geen gegevens	0.012% $ 23.0k
Stephan Reynier	Chief Regulatory & Pharmaceutical Compliance Officer	no data	geen gegevens	0.020% $ 39.1k
Steven Doares	Senior VP of US Manufacturing & Site Head of the Raleigh	4.3yrs	geen gegevens	0.012% $ 24.7k
Laurent Poirot	Senior Vice President of Immunology	no data	geen gegevens	geen gegevens

4.3yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CLLS wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Andre Choulika	Co-Founder	25.8yrs	US$876.60k	1.02% $ 2.0m
David j. Sourdive	Deputy CEO	24.8yrs	US$557.84k	0.31% $ 606.4k
Jean-Pierre Garnier	Independent Non-Executive Chairman	4yrs	US$97.34k	0% $ 0
Laurent Arthaud	Director	13.1yrs	geen gegevens	geen gegevens
Pierre Bastid	Independent Director	13.1yrs	US$97.34k	0.056% $ 110.6k
Rainer Boehm	Independent Director	7.4yrs	US$99.60k	0% $ 0
Dietger Niederwieser	Member of Clinical Advisory Board	7.7yrs	geen gegevens	geen gegevens
Kanti Rai	Member of Clinical Advisory Board	7.8yrs	geen gegevens	geen gegevens
Catherine Bollard	Member of Clinical Advisory Board	7.7yrs	geen gegevens	geen gegevens
Ola Landgren	Member of Clinical Advisory Board	7.7yrs	geen gegevens	geen gegevens
Marcela Maus	Member of Clinical Advisory Board	7.7yrs	geen gegevens	geen gegevens
Stephan Grupp	Member of Clinical Advisory Board	6.2yrs	geen gegevens	geen gegevens

7.7yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CLLS wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.7 jaar).

Cellectis Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Cellectis S.A., Annual General Meeting, Jun 28, 2024

Cellectis Announces Chief Financial Officer Changes

Cellectis S.A. Announces Board Appointments

Cellectis S.A., Annual General Meeting, Jun 27, 2023

Cellectis S.A. Announces the Resignation of Alain Godard as a Member of the Board

Cellectis Appoints Mark Frattini as Chief Medical Officer

Recent updates

Cellectis Presents Multiple Strategies to Enhance Car T-Cell Efficacy in Solid Tumors at the SITC Annual Meeting

Cellectis S.A. to Report Q3, 2024 Results on Nov 04, 2024

Cellectis: Cheap With Promising But Speculative Cancer Therapies

Cibus, Inc. Achieves Positive Initial Field Trial Results for Stacked Gene Editing Herbicide Tolerant Traits in Rice

Cellectis Announces the Publication of A Scientific Article in Nature Communications

Cellectis: 2 Data Readouts Of Blood Cancer Studies By End Of 2024

Cellectis S.A. to Report Q1, 2024 Results on May 28, 2024

Cellectis S.A., Annual General Meeting, Jun 28, 2024

Cellectis Announces Chief Financial Officer Changes

Cellectis S.A. to Report Q1, 2024 Results on May 09, 2024

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

Cellectis S.A. Announces Board Appointments

Cellectis S.A. to Report Q3, 2023 Results on Nov 06, 2023

Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of A Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase ? Syndrome Type 1 (APDS1)

Cellectis S.A. to Report Q2, 2023 Results on Aug 03, 2023

Cibus Global, Ltd. completed the acquisition of Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cellectis S.A., Annual General Meeting, Jun 27, 2023

Cellectis S.A. Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T- Cells at ASGCT 2023

Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on A Novel Treatment Paradigm for Successful Car T Immunotherapy Against Stroma-Rich Solid Tumors

Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023

Cellectis S.A. has completed a Follow-on Equity Offering in the amount of $22 million.

Cellectis S.A. has completed a Follow-on Equity Offering in the amount of $22 million.

Cellectis S.A. announced that it has received $20 million in funding from Cytovia Therapeutics, Inc.

Cellectis S.A. announced that it has received $20 million in funding from Cytovia Therapeutics, Inc.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cellectis S.A. Announces the Resignation of Alain Godard as a Member of the Board

Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL

Cellectis S.A Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML

Cellectis to Showcase Clinical Data from Ameli-01 and Preclinical Data from Ucartcs1 At Ash 2022

Cellectis S.A. to Report Q3, 2022 Results on Nov 03, 2022

Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022

Cellectis Appoints Mark Frattini as Chief Medical Officer

Cellectis S.A. Announces Executive Changes

Cellectis S.A. Announces U.S. Food and Drug Administration Clear Cellectis’ Investigational New Drug Application to Initiate A Phase 1/2A Clinical Trial of UCART20x22 for Patients

FDA clears Cellectis' investigational new drug application for lymphoma treatment

Cellectis S.A. to Report Q2, 2022 Results on Aug 04, 2022

Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors

Cellectis S.A., Annual General Meeting, Jun 28, 2022

Cellectis Presents Research Data on A Novel Immune-Evasive Universal CAR T-Cell At ASGCT

Cellectis S.A. to Report Q1, 2022 Results on May 12, 2022

Cellectis S.A. Releases Preclinical Data on Its Product Candidate UCART20x22 At the American Association for Cancer Research Annual Meeting

Cellectis S.A. to Report Q4, 2021 Results on Mar 03, 2022

Cellectis Appoints Bing C. Wang as Member of its Executive Committee

Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials

Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting

Cellectis Offers An Idiosyncratic Risk Profile With Remarkable Upside Potential

Cellectis: FYE 2021 TALEN CAR-T Data Announcement Should Catalyse Strong Upside

Cellectis S.A. Announces New Product Candidate Pipeline, and Manufacturing and Technologies

Cellectis outlines four new UCART preclinical programs; reveals .HEAL, a genome surgery platform

Cellectis S.A. Announces Preliminary Results from its Phase 1 Balli-01 Clinical Study of Ucart22 in Adults with R/R B-All Presented in Oral Session At 2020 Ash Annual Meeting

Cellectis S.A. to Report Q4, 2020 Results on Mar 04, 2021

Cytovia Therapeutics, Inc. and Cellectis Enter into Strategic Research and Development Collaboration

Cellectis withdraws follow-on offering

Cellectis initiates equity raise of $100M

FDA Lifts Clinical Hold on MELANI-01 Study Evaluating Cellectis’ Product Candidate UCARTCS1 in Multiple Myeloma

FDA lifts clinical hold on Cellectis' early-stage UCARTCS1 study in multiple myeloma

Cellectis Appoints Kyung Nam-Wortman as Executive Vice President, Chief Human Resources Officer

Cellectis S.A. Appoints Jean-Pierre Garnier, Ph.D as Non-Executive Chairman of the Board of Directors

Cellectis EPS misses by $0.10, misses on revenue

Cellectis S.A. to Report Q2, 2020 Results on Aug 05, 2020

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden